ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Extends Revenue Momentum And Raises Full‑Year Guidance

ANI Pharmaceuticals shows accelerating top‑line momentum alongside ample liquidity, while technical signals suggest a near‑term continuation of the recent directional move.

Recent News

On September 28, 2025 the company reported record quarterly results for Q3, citing higher revenues, expanded gross margins, and an upward revision to full‑year 2025 guidance. On September 26, 2025 the remaining convertible preferred shares converted into common shares, increasing share count. On October 9, 2025 Truist Securities maintained coverage with a Hold rating while analysts’ consensus one‑year price target clustered near $105.64.

Technical Analysis

ADX at 46.51 registers very strong trend strength; that intensity supports the recent directional move and increases the likelihood that momentum will sustain price action near current levels.

DI+ shows a dip & reversal while DI− shows a peak & reversal, a paired bullish signal implying directional buyers have regained control after a recent pullback.

MACD presents a dip & reversal (MACD increasing) yet remains negative at −2.76 and below the signal line at −2.07, indicating bullish momentum improving from a low base but not yet confirming a full bullish crossover.

MRO reads 2.59 (positive), which indicates price currently sits above WMDST’s target and therefore carries a bias toward consolidation or downward pressure absent fresh upside catalysts.

RSI at 46.18 with a dip & reversal shows momentum recovering from lower levels while remaining below neutral 50; that pattern favors further mean reversion toward nearby moving averages rather than an immediate breakout.

Price closed at $83.22, trading above the 200‑day average of $74.58 but below the 50‑day average of $90.40 and the 20‑day average of $84.27; the 12‑day EMA trends decreasing, suggesting short‑term resistance near the 20‑day and 50‑day averages and support around the lower Bollinger band at $79.67.

 


Fundamental Analysis

Revenue growth shows a 4.33% year‑over‑year increase with sequential revenue growth of 7.61% QoQ, supporting the company’s recent upward guidance.

Gross margin at 59.01% and EBIT margin at 16.91% indicate strong profitability versus the industry peer mean EBIT margin of 24.54% and median of 30.689%; EBIT margin sits below the industry peer mean and median but above the industry low. EBIT margin expanded QoQ by 123.94% while contracting YoY by 186.01%, reflecting significant quarter‑to‑quarter operating leverage dynamics tied to product mix and recent acquisitions.

EPS came in at $2.04 versus an estimate of $1.77, producing a $0.27 beat and a 15.25% surprise, which underpinned analyst revisions and the guidance raise.

Balance sheet and liquidity metrics present strength: cash and short‑term investments total $271.47M, cash ratio at 1.00, current ratio at 2.58, and a cash conversion cycle of 194 days. Net debt stands at $357.7M with total debt of $620.31M and debt‑to‑assets of 44.05% (debt‑to‑equity 122.64%), reflecting leverage that remains serviceable given an interest coverage ratio of 8.15.

Valuation multiples show a trailing P/E of 43.70 and forward P/E of 61.28, while price‑to‑book equals 3.96 (industry peer mean book multiple ~4.53, median ~5.34). Free cash flow yield registers about 1.89% while free cash flow growth shows recent contraction; operating cash flow and free cash conversion show positive cash generation relative to net income (cash‑to‑earnings >100%).

WMDST values the stock as under‑valued based on the combination of accelerating revenue, robust gross margins, sizeable cash reserves, and WMDST’s enterprise valuation analysis relative to projected cash flows.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-09-30
REPORT DATE: 2025-11-07
NEXT REPORT DATE: 2026-02-06
CASH FLOW  Begin Period Cash Flow 217.8 M
 Operating Cash Flow 44.1 M
 Capital Expenditures -6.16 M
 Change In Working Capital -17.84 M
 Dividends Paid -344.00 K
 Cash Flow Delta 44.8 M
 End Period Cash Flow 262.6 M
 
INCOME STATEMENT REVENUE
 Total Revenue 227.8 M
 Forward Revenue 66.4 M
COSTS
 Cost Of Revenue 93.4 M
 Depreciation 22.6 M
 Depreciation and Amortization 22.6 M
 Research and Development 12.3 M
 Total Operating Expenses 205.0 M
PROFITABILITY
 Gross Profit 134.4 M
 EBITDA 61.2 M
 EBIT 38.5 M
 Operating Income 22.8 M
 Interest Income
 Interest Expense 4.7 M
 Net Interest Income -4.73 M
 Income Before Tax 33.8 M
 Tax Provision 7.2 M
 Tax Rate 21.3 %
 Net Income 26.6 M
 Net Income From Continuing Operations 26.6 M
EARNINGS
 EPS Estimate 1.77
 EPS Actual 2.04
 EPS Difference 0.27
 EPS Surprise 15.254 %
 Forward EPS 1.38
 
BALANCE SHEET ASSETS
 Total Assets 1.4 B
 Intangible Assets 562.3 M
 Net Tangible Assets -56.48 M
 Total Current Assets 698.4 M
 Cash and Short-Term Investments 271.5 M
 Cash 262.6 M
 Net Receivables 252.6 M
 Inventory 146.5 M
 Long-Term Investments
LIABILITIES
 Accounts Payable 69.8 M
 Short-Term Debt 15.2 M
 Total Current Liabilities 270.6 M
 Net Debt 357.7 M
 Total Debt 620.3 M
 Total Liabilities 902.3 M
EQUITY
 Total Equity 505.8 M
 Retained Earnings -50.59 M
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 22.52
 Shares Outstanding 22.462 M
 Revenue Per-Share 10.14
VALUATION
 Market Capitalization 2.0 B
 Enterprise Value 2.4 B
 Enterprise Multiple 38.442
Enterprise Multiple QoQ -25.977 %
Enterprise Multiple YoY -146.837 %
Enterprise Multiple IPRWA high: 127.79
mean: 57.87
median: 47.344
ANIP: 38.442
low: -89.639
 EV/R 10.32
CAPITAL STRUCTURE
 Asset To Equity 2.784
 Asset To Liability 1.561
 Debt To Capital 0.551
 Debt To Assets 0.441
Debt To Assets QoQ -4.82 %
Debt To Assets YoY 7822.842 %
Debt To Assets IPRWA high: 0.914
ANIP: 0.441
mean: 0.326
median: 0.285
low: 0.001
 Debt To Equity 1.226
Debt To Equity QoQ -13.827 %
Debt To Equity YoY 6859.989 %
Debt To Equity IPRWA high: 2.751
ANIP: 1.226
mean: 0.819
median: 0.596
low: -1.72
PRICE-BASED VALUATION
 Price To Book (P/B) 3.958
Price To Book QoQ 5.419 %
Price To Book YoY 28.811 %
Price To Book IPRWA high: 10.347
median: 5.339
mean: 4.535
ANIP: 3.958
low: -1.956
 Price To Earnings (P/E) 43.696
Price To Earnings QoQ 21.116 %
Price To Earnings YoY -1.108 %
Price To Earnings IPRWA high: 117.495
median: 62.821
mean: 60.83
ANIP: 43.696
low: -77.541
 PE/G Ratio 3.277
 Price To Sales (P/S) 8.789
Price To Sales QoQ 13.277 %
Price To Sales YoY 4.504 %
Price To Sales IPRWA high: 26.038
median: 17.64
mean: 15.103
ANIP: 8.789
low: 1.463
FORWARD MULTIPLES
Forward P/E 61.278
Forward PE/G 4.596
Forward P/S 30.133
EFFICIENCY OPERATIONAL
 Operating Leverage 18.172
ASSET & SALES
 Asset Turnover Ratio 0.166
Asset Turnover Ratio QoQ 3.242 %
Asset Turnover Ratio YoY 23.268 %
Asset Turnover Ratio IPRWA high: 0.401
ANIP: 0.166
mean: 0.128
median: 0.124
low: 0.005
 Receivables Turnover 0.953
Receivables Turnover Ratio QoQ 0.503 %
Receivables Turnover Ratio YoY 16.391 %
Receivables Turnover Ratio IPRWA high: 2.105
median: 1.242
mean: 1.212
ANIP: 0.953
low: 0.489
 Inventory Turnover 0.656
Inventory Turnover Ratio QoQ 21.176 %
Inventory Turnover Ratio YoY 42.184 %
Inventory Turnover Ratio IPRWA high: 1.758
ANIP: 0.656
mean: 0.646
median: 0.53
low: -0.174
 Days Sales Outstanding (DSO) 95.785
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 193.881
Cash Conversion Cycle Days QoQ -3.673 %
Cash Conversion Cycle Days YoY -19.587 %
Cash Conversion Cycle Days IPRWA high: 364.324
ANIP: 193.881
median: 118.08
mean: 44.669
low: -577.709
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.532
 CapEx To Revenue -0.027
 CapEx To Depreciation -0.272
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 1.1 B
 Net Invested Capital 1.1 B
 Invested Capital 1.1 B
 Net Tangible Assets -56.48 M
 Net Working Capital 427.8 M
LIQUIDITY
 Cash Ratio 1.003
 Current Ratio 2.581
Current Ratio QoQ 1.449 %
Current Ratio YoY -5.949 %
Current Ratio IPRWA high: 3.415
ANIP: 2.581
mean: 0.927
median: 0.836
low: 0.352
 Quick Ratio 2.04
Quick Ratio QoQ 4.054 %
Quick Ratio YoY 3.806 %
Quick Ratio IPRWA high: 2.374
ANIP: 2.04
mean: 0.687
median: 0.599
low: 0.103
COVERAGE & LEVERAGE
 Debt To EBITDA 10.143
 Cost Of Debt 0.599 %
 Interest Coverage Ratio 8.15
Interest Coverage Ratio QoQ 177.655 %
Interest Coverage Ratio YoY -165.137 %
Interest Coverage Ratio IPRWA high: 31.584
mean: 13.44
median: 8.475
ANIP: 8.15
low: -26.093
 Operating Cash Flow Ratio 0.108
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 76.045
DIVIDENDS
 Dividend Coverage Ratio 77.375
 Dividend Payout Ratio 0.013
 Dividend Rate 0.02
 Dividend Yield 0.0
PERFORMANCE GROWTH
 Asset Growth Rate 4.851 %
 Revenue Growth 7.779 %
Revenue Growth QoQ 7.608 %
Revenue Growth YoY 4.332 %
Revenue Growth IPRWA high: 25.317 %
ANIP: 7.779 %
mean: 2.56 %
median: 0.502 %
low: -26.278 %
 Earnings Growth 13.333 %
Earnings Growth QoQ 126.675 %
Earnings Growth YoY -57.502 %
Earnings Growth IPRWA high: 85.714 %
ANIP: 13.333 %
median: 1.0 %
mean: -6.446 %
low: -81.013 %
MARGINS
 Gross Margin 59.006 %
Gross Margin QoQ -8.801 %
Gross Margin YoY 2.66 %
Gross Margin IPRWA high: 105.313 %
mean: 71.036 %
median: 69.562 %
ANIP: 59.006 %
low: -7.888 %
 EBIT Margin 16.912 %
EBIT Margin QoQ 123.941 %
EBIT Margin YoY -186.009 %
EBIT Margin IPRWA high: 71.511 %
median: 30.689 %
mean: 24.54 %
ANIP: 16.912 %
low: -82.97 %
 Return On Sales (ROS) 10.022 %
Return On Sales QoQ 39.66 %
Return On Sales YoY -150.969 %
Return On Sales IPRWA high: 31.586 %
median: 29.992 %
mean: 28.695 %
ANIP: 10.022 %
low: -83.009 %
CASH FLOW
 Free Cash Flow (FCF) 37.9 M
 Free Cash Flow Yield 1.892 %
Free Cash Flow Yield QoQ -54.963 %
Free Cash Flow Yield YoY 235.461 %
Free Cash Flow Yield IPRWA high: 12.255 %
mean: 4.028 %
ANIP: 1.892 %
median: 1.889 %
low: -18.726 %
 Free Cash Growth -45.007 %
Free Cash Growth QoQ -112.68 %
Free Cash Growth YoY -1.665 %
Free Cash Growth IPRWA high: 289.614 %
mean: 92.933 %
median: 36.016 %
ANIP: -45.007 %
low: -206.393 %
 Free Cash To Net Income 1.424
 Cash Flow Margin 12.884 %
 Cash Flow To Earnings 1.103
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.935 %
Return On Assets QoQ 198.151 %
Return On Assets YoY -188.397 %
Return On Assets IPRWA high: 4.024 %
median: 2.668 %
mean: 2.17 %
ANIP: 1.935 %
low: -18.394 %
 Return On Capital Employed (ROCE) 3.387 %
 Return On Equity (ROE) 0.053
Return On Equity QoQ 168.881 %
Return On Equity YoY -188.392 %
Return On Equity IPRWA high: 0.177
median: 0.065
ANIP: 0.053
mean: 0.045
low: -0.484
 DuPont ROE 5.648 %
 Return On Invested Capital (ROIC) 2.692 %
Return On Invested Capital QoQ 119.755 %
Return On Invested Capital YoY -82.416 %
Return On Invested Capital IPRWA high: 14.18 %
mean: 4.894 %
median: 4.254 %
ANIP: 2.692 %
low: -11.808 %

Six-Week Outlook

Near term, the strong ADX and bullish directional indicator configuration favor continuation of the recent trend, but MACD remains below its signal line and MRO signals price above WMDST’s target, so upside requires confirmation via a MACD crossover or sustained closes above the 20‑day average (~$84.3) and resistance near $87.6 (super trend upper). Conversely, failure to hold the lower Bollinger band near $79.7 would likely produce short‑term consolidation toward the 200‑day average. Monitor volume relative to the 10‑day and 50‑day averages for conviction; rising volume on price advances supports continuation, while heavy distribution suggests a pullback may follow.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) engages in the development, manufacturing, and marketing of both branded and generic prescription medications. Based in Baudette, Minnesota, ANI Pharmaceuticals has been serving the healthcare sector since 2001, focusing on the needs of patients in the United States and Canada. The company’s extensive product lineup includes oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent pharmaceuticals. In addition to its proprietary products, ANI Pharmaceuticals provides contract development and manufacturing services, leveraging its expertise in pharmaceutical production to cater to diverse client needs. ANI Pharmaceuticals has built a comprehensive distribution network, ensuring its products reach a broad spectrum of consumers. This network includes retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals, facilitating wide accessibility of their medications. The company remains committed to expanding its product offerings and enhancing manufacturing capabilities. Through continuous innovation and a focus on quality, ANI Pharmaceuticals aims to improve patient outcomes and address unmet medical needs, maintaining its position as a reliable partner in the biopharmaceutical industry.



© 2025 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.